← Leaderboards
Yolonda L Colson
Boston University (Charles River Campus)
$10,834,927
Attributed
$22,670,480
Total exposure
13
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.3M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$22,622,487 · 12
AHRQ$47,993 · 1
By mechanism
R01$19,851,077 · 10
U01$2,539,139 · 1
R29$232,271 · 1
R13$47,993 · 1
Top collaborators
- Mark W Grinstaff37 shared
- Chandrajit Premanand Raut8 shared
- Wilson Wong6 shared
- Kebin Liu5 shared
- Nicholas Hunter Oberlies5 shared
- Orian S Shirihai5 shared
Most similar at Boston University (Charles River Campus)
Same institution · by research overlap
- Mark W Grinstaff$24,362,733
- Orian S Shirihai$11,530,700
- Danielle Fitzgerald$89,896
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoTumorPreventTissuesExcisionCollaborationsExperimental DesignsOperative Surgical ProceduresPharmaceutical PreparationsDoseSitePaclitaxelPolymersRecurrenceExperimental StudyPropertyNeoplastic CellBaseCytotoxicityIn VitroAnimalsMouse ModelImplantationPrevention
Grant awards (50)
Supratherapeutic PTX Buttresses Reduce Locoregional Recurrence Rates Following Surgery for Soft Tissue Sarcomas$712,043
R01 · FY2025 · CA
Modified saRNA Encoded BiTEs for Lung Cancer$635,248
R01 · FY2025 · CA
Biodegradable, Biocompatible Pressure Sensitive Adhesives$594,799
R01 · FY2025 · HL
Precise tumor targeting with logic CAR circuits$323,559
U01 · FY2025 · CA
Supratherapeutic PTX Buttresses Reduce Locoregional Recurrence Rates Following Surgery for Soft Tissue Sarcomas$676,443
R01 · FY2024 · CA
Biodegradable, Biocompatible Pressure Sensitive Adhesives$545,646
R01 · FY2024 · HL
Precise tumor targeting with logic CAR circuits$525,026
U01 · FY2024 · CA
Supratherapeutic PTX Buttresses Reduce Locoregional Recurrence Rates Following Surgery for Soft Tissue Sarcomas$695,566
R01 · FY2023 · CA
Precise tumor targeting with logic CAR circuits$553,669
U01 · FY2023 · CA
Biodegradable, Biocompatible Pressure Sensitive Adhesives$520,496
R01 · FY2023 · HL
SUPERHYDROPHOBIC DRUG LOADED BUTTRESSES FOR PREVENTION OF LUNGTUMOR RECURRENCE$505,038
R01 · FY2023 · CA
OPTIMIZATION OF NANOPARTICLE TUMOR-LOCALIZATION AND DRUG-LOADINGFOR TREATING MESOTHELIOMA$500,083
R01 · FY2023 · CA
Supratherapeutic PTX Buttresses Reduce Locoregional Recurrence Rates Following Surgery for Soft Tissue Sarcomas$749,261
R01 · FY2022 · CA
Biodegradable, Biocompatible Pressure Sensitive Adhesives$555,638
R01 · FY2022 · HL
Precise tumor targeting with logic CAR circuits$554,582
U01 · FY2022 · CA
OPTIMIZATION OF NANOPARTICLE TUMOR-LOCALIZATION AND DRUG-LOADINGFOR TREATING MESOTHELIOMA$539,833
R01 · FY2022 · CA
SUPERHYDROPHOBIC DRUG LOADED BUTTRESSES FOR PREVENTION OF LUNGTUMOR RECURRENCE$468,259
R01 · FY2022 · CA
TUMOR SPECIFIC DELIVERY OF VERTICILLIN A OVERCOMES EPIGENETIC SILENCING RESPONSIBLE FOR DRUG RESISTANCE$452,836
R01 · FY2022 · CA
TUMOR SPECIFIC DELIVERY OF VERTICILLIN A OVERCOMES EPIGENETIC SILENCING RESPONSIBLE FOR DRUG RESISTANCE$610,821
R01 · FY2021 · CA
Precise tumor targeting with logic CAR circuits$582,303
U01 · FY2021 · CA
OPTIMIZATION OF NANOPARTICLE TUMOR-LOCALIZATION AND DRUG-LOADING FOR TREATING MESOTHELIOMA$568,654
R01 · FY2021 · CA
SUPERHYDROPHOBIC DRUG LOADED BUTTRESSES FOR PREVENTION OF LUNG TUMOR RECURRENCE$437,722
R01 · FY2021 · CA
OPTIMIZATION OF NANOPARTICLE TUMOR-LOCALIZATION AND DRUG-LOADING FOR TREATING MESOTHELIOMA$569,979
R01 · FY2020 · CA
TUMOR SPECIFIC DELIVERY OF VERTICILLIN A OVERCOMES EPIGENETIC SILENCING RESPONSIBLE FOR DRUG RESISTANCE$526,098
R01 · FY2020 · CA
SUPERHYDROPHOBIC DRUG LOADED BUTTRESSES FOR PREVENTION OF LUNG TUMOR RECURRENCE$439,002
R01 · FY2020 · CA
OPTIMIZATION OF NANOPARTICLE TUMOR-LOCALIZATION AND DRUG-LOADING FOR TREATING MESOTHELIOMA$534,718
R01 · FY2019 · CA
TUMOR SPECIFIC DELIVERY OF VERTICILLIN A OVERCOMES EPIGENETIC SILENCING RESPONSIBLE FOR DRUG RESISTANCE$489,515
R01 · FY2019 · CA
Efficacy and Safety of a Novel, Implantable Drug-eluting Film in Sarcoma$404,583
R01 · FY2019 · EB · contact PI
SUPERHYDROPHOBIC DRUG LOADED BUTTRESSES FOR PREVENTION OF LUNG TUMOR RECURRENCE$355,982
R01 · FY2019 · CA
TUMOR SPECIFIC DELIVERY OF VERTICILLIN A OVERCOMES EPIGENETIC SILENCING RESPONSIBLE FOR DRUG RESISTANCE$608,862
R01 · FY2018 · CA
Efficacy and Safety of a Novel, Implantable Drug-eluting Film in Sarcoma$421,129
R01 · FY2018 · EB · contact PI
Efficacy and Safety of a Novel, Implantable Drug-eluting Film in Sarcoma$407,644
R01 · FY2017 · EB · contact PI
Efficacy and Safety of a Novel, Implantable Drug-eluting Film in Sarcoma$430,368
R01 · FY2016 · EB · contact PI
Flexible, Conformal, Polymeric Films for Lung Resection Margins$336,653
R01 · FY2014 · CA
Flexible, Conformal, Polymeric Films for Lung Resection Margins$326,094
R01 · FY2013 · CA
Flexible, Conformal, Polymeric Films for Lung Resection Margins$345,579
R01 · FY2012 · CA
Innovative Clinical Pathways in Lung Cancer Care for Vulnerable Populations$47,993
R13 · FY2012 · HS · contact PI
Flexible, Conformal, Polymeric Films for Lung Resection Margins$361,745
R01 · FY2011 · CA
NIR Imaging of Sentinel Nodes in Lung Cancer: Finding Micrometastases$350,078
R01 · FY2011 · CA · contact PI
NIR Imaging of Sentinel Nodes in Lung Cancer: Finding Micrometastases$360,905
R01 · FY2010 · CA · contact PI
NIR Imaging of Sentinel Nodes in Lung Cancer: Finding Micrometastases$360,853
R01 · FY2009 · CA · contact PI
NIR Imaging of Sentinel Nodes in Lung Cancer: Finding Micrometastases$398,197
R01 · FY2008 · CA · contact PI
Mechanism of Facilitating Cell-Mediated Tx Tolerance$98,000
R01 · FY2007 · HL · contact PI
Mechanism of Facilitating Cell-Mediated Tx Tolerance$500,047
R01 · FY2006 · HL · contact PI
Mechanism of Facilitating Cell-Mediated Tx Tolerance$512,080
R01 · FY2005 · HL
Mechanism of Facilitating Cell-Mediated Tx Tolerance$432,500
R01 · FY2004 · HL
Mechanism of Facilitating Cell-Mediated Tx Tolerance$79,580
R01 · FY2004 · HL
Mechanism of Facilitating Cell-Mediated Tx Tolerance$432,500
R01 · FY2003 · HL
FACILITATING CELL INDUCED TOLERANCE IN ORGAN TRANSPLANTS$116,114
R29 · FY2001 · AI
FACILITATING CELL INDUCED TOLERANCE IN ORGAN TRANSPLANTS$116,157
R29 · FY2000 · AI